JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Janux Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.74+0.23 (+1.39%)
Close on Oct 19, 2026
- Market cap
- $1.05B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$10.02 (−37.44%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Janux Therapeutics, Inc. grew revenue 5367.0% to $24.00M over the twelve months to Jun 30, 2026. Free cash flow was -$41.93M.
Revenue
$24.00M
+5367.0% vs. a year earlier
Operating income
-$143.56M
TTM Q2 2026
Free cash flow
-$41.93M
TTM Q2 2026
EPS, diluted
-$1.64
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.05B
- P/E ratio
- –
- Price to sales
- 43.90
- Price to book
- 1.14
- Dividend yield
- –
- Free cash flow yield
- -3.98%
Fundamentals
- Revenue
- $24.00M
- Net income
- -$102.59M
- EPS, diluted
- -$1.64
- Free cash flow
- -$41.93M
- Book value per share
- $14.74
- Diluted shares
- 63M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$24.00M+5367.0% YoY
Operating income
-$143.56M
Net income
-$102.59M
EPS, diluted
-$1.64
Free cash flow
-$41.93M
Reported periodTrailing twelve months